13 January 2026   Edinburgh-based CRO Axol Bioscience  announces  it has raised $2.8M in funding led by US life sciences specialist BroadOak Capital Partners. This investment will build upon Axol's double-digit revenue growth in 2025 to further support the development of its human-relevant in vitro disease models and its expansion to the US market.   "We’re proud to partner with BroadOak, a global leader in life sciences investing. Their expertise and support, alongside our l